Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment inclu ...
President Jim Kalua has expressed satisfaction with the strides the association is making, particularly after investing MK10.4 million in a medical scheme for its members. According to Kalua, the ...